• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trials
    • Search Clinical Trials
    • Patient Notification System
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Clinical Trial Listings
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • Events
    • Newsletters
    • JobWatch
    • White Papers
    • Patient Education
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Trial Listings
  • Advertise
  • COVID-19
  • iConnect
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Teralys Capital, Lilly invest in new $150 million fund for life sciences

Teralys Capital, Lilly invest in new $150 million fund for life sciences

May 30, 2012
CenterWatch Staff

Teralys Capital has invested $65 million, along with other amounts from Eli Lilly and other partners, in TVM Life Science Ventures VII, which closed on an initial size of $150 million.

The fund, which will focus primarily on early stage drug development and life sciences company opportunities, enables a new investment model in Quebec, involving the formation by the fund of single therapeutic asset companies. The fund, domiciled in Montreal, is expected to benefit the entire local life sciences ecosystem of researchers, entrepreneurs, business partners and service providers.

"There are many challenges today in financing early-stage life sciences innovation,” said Darren Carroll, vice president of corporate business development, Eli Lilly. “We are hopeful that the project-focused company model will allow for greater cost efficiency, thus focusing development efforts on the most promising therapeutic products.

The fund meets the three key requirements set by Teralys Capital to successfully invest in the life sciences sector and to better support businesses in Quebec: an optimal fund size of at least $150 million, the reach of a proven international network and the participation of key strategic partners. Teralys Capital and Lilly are joined in the fund by leading institutional investors including Fondaction, BDC Venture Capital and Advantus Capital Management, a subsidiary of the Minnesota Life Insurance.

As part of the arrangement, Lilly will establish a Canadian unit of Chorus in Montreal. Chorus, an autonomous unit of Lilly, is a global-early-phase drug development network that focuses on designing and executing lean and highly-focused development plans that cost-effectively progress potential medicines from candidate selection to clinical proof-of-concept. Chorus draws on internal Lilly skills, CROs and external consultants with very specific areas of expertise. Chorus Canada will work with development service providers across the province and elsewhere to offer development services to project-focused companies based primarily in Quebec.

“This new investment will support a more efficient way to develop innovation in Canada and will hopefully lead to improved outcomes for individual patients around the world,” said Michael Mason, president and general manager, Eli Lilly Canada. “Establishing a Chorus division in Montreal illustrates Lilly's commitment to 'research without walls' and to investing in research and development in Canada. We are proud that Chorus Canada will employ scientific experts in Montreal, and contribute to job creation and ongoing employment within this industry in the province and Canada."

Upcoming Events

  • 26Jan

    Reducing Complexity in Starting Clinical Trials – More Patients, Faster Startup

  • 27Jan

    Medical Device Clinical Trials in China: Latest Regulatory Developments

  • 11Feb

    Lab X.0: Addressing Quality and Compliance Challenges in Laboratory Operations in the COVID-19 All-Digital Era

  • 23Mar

    Data Integrity for GCP Professionals: Core Requirements, Expectations and Challenges

  • 26Apr

    MAGI's Clinical Research vConference — Spring 2021

Featured Products

  • Regenerative Medicine – Steps to Accelerate Development : PDF

    Regenerative Medicine: Steps to Accelerate Development

  • Clinical Trial Agreements — A Guide to Key Words and Phrases : PDF

    Clinical Trial Agreements: A Guide to Key Words and Phrases

Featured Stories

  • TechInnovation-360x240.png

    Pace of Technology Innovation in Trials Could Slow After Pandemic Eases

  • AskTheExperts-360x240.png

    Ask the Experts: Certifying and Maintaining Copies of Original Source Documents

  • Resources-360x240.png

    Trial Complexity, Endpoints Continue to Increase, Stretching Site Resources

  • FocusinRed-360x240.png

    Return to Focus on Risk Management Postpandemic Could Prove Challenging to Sites

Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

The information you need to adapt your monitoring plan to changing times.

Learn More Here
  • About Us
  • Contact Us
  • Privacy Policy
  • Do Not Sell My Personal Information

Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 617.948.5100 – Toll free 866.219.3440

Copyright © 2021. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing